靶向胆囊收缩素-2受体的微胃泌素类似物177Lu-DOTA-PP-F11N:蛋白酶抑制剂能否进一步改善体内分布
转移性甲状腺髓样癌全身治疗选择有限,靶向胆囊收缩素-2受体的放射性胃泌素类似物是研究方向,但体内酶降解可能降低疗效。本研究比较化学稳定化类似物177Lu-DOTA-PP-F11N与另两种参考类似物的体外稳定性和体内分布,并评估联用蛋白酶抑制剂磷酰二肽或塞奥芬的效果,同时首次报告177Lu-DOTA-PP-F11N的人体数据。
要点
- 177Lu-DOTA-PP-F11N在MZ-CRC-1肿瘤摄取为20.7 ± 1.71 %IA/g,几乎是177Lu-DOTA-PP-F11的11.2 ± 2.94 %IA/g的两倍,P = 0.0002。
- 联用磷酰二肽后177Lu-DOTA-PP-F11N在MZ-CRC-1肿瘤摄取为20.7 ± 1.71 vs 15.6 ± 3.80 %IA/g,P < 0.05,未见提高甚至降低。
- 首次人体数据示177Lu-DOTA-PP-F11N在肿瘤、胃、肾和结肠高摄取,胃可能是除肾外的潜在剂量限制器官。
核心结论
- 无蛋白酶抑制剂时177Lu-DOTA-PP-F11N的表现与有抑制剂时177Lu-DOTA-MG11的表现相当;作者认为人体应用单一化合物而无需不必要添加剂更为可取。
- 初步临床数据提示胃是除肾之外的潜在剂量限制器官。
研究设计与样本
- 体外评估三种类似物对多种细胞外和细胞内内切蛋白酶的稳定性,并使用人甲状腺髓样癌MZ-CRC-1细胞系和转染的A431-CCK2R(+)细胞系进行体外评价。
- 在MZ-CRC-1与A431-CCK2R(+)双异种移植模型中,于注射后4小时评估无和有磷酰二肽及塞奥芬时的生物分布,并进行177Lu-DOTA-PP-F11N(无和有磷酰二肽)放射自显影和NanoSPECT/CT。
- 采集一例转移性甲状腺髓样癌患者的177Lu-DOTA-PP-F11N SPECT/CT图像,首次报告该化合物的临床数据。
主要发现
- natLu-DOTA-PP-F11N较其他类似物更不易被脑啡肽酶作用,而细胞内半胱氨酸蛋白酶如组织蛋白酶-L可能参与胃泌素类似物的降解。
- 所有放射性示踪剂在MZ-CRC-1肿瘤中的摄取高于A431-CCK2R(+),显然是因为MZ-CRC-1细胞上结合位点数量更多。
- 177Lu-DOTA-PP-F11N与177Lu-DOTA-PP-F11的生物分布相同,但MZ-CRC-1肿瘤摄取几乎翻倍(20.7 ± 1.71 vs 11.2 ± 2.94 %IA/g,P = 0.0002)。
- 联用磷酰二肽或塞奥芬显著提高177Lu-DOTA-MG11在CCK2R(+)肿瘤和胃中的摄取;对177Lu-DOTA-PP-F11的影响较弱,而对177Lu-DOTA-PP-F11N未见影响甚至降低(MZ-CRC-1肿瘤中20.7 ± 1.71 vs 15.6 ± 3.80[联用磷酰二肽]%IA/g,P < 0.05)。
- 首次临床数据显示177Lu-DOTA-PP-F11N在肿瘤、胃、肾和结肠中高蓄积。
关键数值与推荐
- 177Lu-DOTA-PP-F11N的化学结构为177Lu-DOTA-(dGlu)6-Ala-Tyr-Gly-Trp-Nle-Asp-Phe-NH2。
- 参考类似物177Lu-DOTA-MG11结构为177Lu-DOTA-dGlu-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2,177Lu-DOTA-PP-F11结构为177Lu-DOTA-(dGlu)6-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2。
- 生物分布于注射后4小时评估,蛋白酶抑制剂为磷酰二肽和塞奥芬。
临床怎么用
- 原文结论认为无蛋白酶抑制剂时177Lu-DOTA-PP-F11N的表现与有抑制剂时177Lu-DOTA-MG11相当,作者认为人体应用单一化合物而无需不必要添加剂更为可取。
- 初步临床数据提示胃是除肾之外的潜在剂量限制器官。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Patients with metastatic medullary thyroid cancer (MTC) have limited systemic treatment options. The use of radiolabeled gastrin analogs targeting the cholecystokinin-2 receptor (CCK2R) is an attractive approach. However, their therapeutic efficacy is presumably decreased by their enzymatic degradation in vivo. We aimed to investigate whether the chemically stabilized analog 177Lu-DOTA-PP-F11N (177Lu-DOTA-(dGlu)6-Ala-Tyr-Gly-Trp-Nle-Asp-Phe-NH2) performs better than reference analogs with varying in vivo stability, namely 177Lu-DOTA-MG11 (177Lu-DOTA-dGlu-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2) and 177Lu-DOTA-PP-F11 (177Lu-DOTA-(dGlu)6-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2), and whether the use of protease inhibitors further improves CCKR2 targeting. First human data on 177Lu-DOTA-PP-F11N are also reported. Methods: In vitro stability of all analogs was assessed against a panel of extra- and intracellular endoproteases, whereas their in vitro evaluation was performed using the human MTC MZ-CRC-1 and the transfected A431-CCK2R(+) cell lines. Biodistribution without and with the protease inhibitors phosphoramidon and thiorphan was assessed 4 h after injection in MZ-CRC-1 and A431-CCK2R(+) dual xenografts. Autoradiography of 177Lu-DOTA-PP-F11N (without and with phosphoramidon) and NanoSPECT/CT were performed. SPECT/CT images of 177Lu-DOTA-PP-F11N in a metastatic MTC patient were also acquired. Results:natLu-DOTA-PP-F11N is less of a substrate for neprilysins than the other analogs, whereas intracellular cysteine proteases, such as cathepsin-L, might be involved in the degradation of gastrin analogs. The uptake of all radiotracers was higher in MZ-CRC-1 tumors than in A431-CCK2R(+), apparently because of the higher number of binding sites on MZ-CRC-1 cells. 177Lu-DOTA-PP-F11N had the same biodistribution as 177Lu-DOTA-PP-F11; however, uptake in the MZ-CRC-1 tumors was almost double (20.7 ± 1.71 vs. 11.2 ± 2.94 %IA [percentage injected activity]/g, P = 0.0002). Coadministration of phosphoramidon or thiorphan increases 177Lu-DOTA-MG11 uptake significantly in the CCK2R(+) tumors and stomach. Less profound was the effect on 177Lu-DOTA-PP-F11, whereas no influence or even reduction was observed for 177Lu-DOTA-PP-F11N (20.7 ± 1.71 vs. 15.6 ± 3.80 [with phosphoramidon] %IA/g, P < 0.05 in MZ-CRC-1 tumors). The first clinical data show high 177Lu-DOTA-PP-F11N accumulation in tumors, stomach, kidneys, and colon. Conclusion: The performance of 177Lu-DOTA-PP-F11N without protease inhibitors is as good as the performance of 177Lu-DOTA-MG11 in the presence of inhibitors. The human application of single compounds without unessential additives is preferable. Preliminary clinical data spotlight the stomach as a potential dose-limiting organ besides the kidneys.
引用
- Sauter AW, Mansi R, Hassiepen U, et al. Targeting of the Cholecystokinin-2 Receptor with the Minigastrin Analog 177Lu-DOTA-PP-F11N: Does the Use of Protease Inhibitors Further Improve In Vivo Distribution? J Nucl Med. 2018. PMID: 30002107. doi:10.2967/jnumed.118.207845
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。